KR970706830A - 2, 2'-디티오-비스(에탄설포네이트)(디메스나)와 조합된 시스플라틴의 조성물(composition of cisplatin in combination with 2, 2'-dithio-bis (ethanesulfonate) (dimesna) - Google Patents
2, 2'-디티오-비스(에탄설포네이트)(디메스나)와 조합된 시스플라틴의 조성물(composition of cisplatin in combination with 2, 2'-dithio-bis (ethanesulfonate) (dimesna)Info
- Publication number
- KR970706830A KR970706830A KR1019970703171A KR19970703171A KR970706830A KR 970706830 A KR970706830 A KR 970706830A KR 1019970703171 A KR1019970703171 A KR 1019970703171A KR 19970703171 A KR19970703171 A KR 19970703171A KR 970706830 A KR970706830 A KR 970706830A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- cisplatin
- dithio
- bis
- ethanesulfonate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
시스플라턴을 2,2'-디티오-비스(에탄설포네이트)의 약학적 허용 형태와 함께 투여하는 것은 시스플라틴의 신독성과 골수억제를 감소시키며 시스플라틴의 항암작용을 감소시킨다. 바람직하게는 시스플라틴과 설포네이트는 조성물, 특히 염소 이온과 나트륨 및 수소 양이온을 함유하는 살균된 주사가능한 용액으로 제제화된다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (10)
- 시스플라틴과 2,2'-디티오-비스(에탄설포네이트)의 약학적 허용 형태를 포함하는, 암환자에게 투여하기에 적합한 조성물.
- 제1항에 있어서, pH 2 내지 6의 살균된 주사가능한 수용액 또는 현탁액 형태의 조성물.
- 제2항에 있어서, pH가 4 내지 6인 조성물.
- 제2항 또는 3항에 있어서, 추가로 완충용액을 포함하는 조성물.
- 제2,3,4항에 있어서, 염소 음이온과 나트륨 양이온 및 수소 양이온을 포함하는 조성물.
- 제5항에 있어서, 0.1 내지 1.0㎎/㎖의 시스플라틴, 1.0 내지 320㎎/㎖의 설포네이트, 10 내지 25㎎/㎖의 염화나트륨 및 정의된 pH를 제공하기 위한 염산 또는 인산을 포함하는 조성물.
- 제6항에 있어서, 추가로 10 내지 25㎎/㎖의 만니톨을 포함하는 조성물.
- 제1,2,3,4,5,6 또는 7항에 있어서, 동결건조물 형태의 조성물.
- 환자의 혈액에 시스플라틴과 설포네이트가 공존하도록 시스플라틴과 함께 거의 동시에 또는 순차적으로 환자에게 투여하기 위한 약제의 제조에서 2,2'-디티오-비스(에탄설포네이트)의 약학적 허용형태의 이용.
- 제9항에 있어서, 설포네이트의 수용액의 동결건조 형태의 이용.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/338,379 US5789000A (en) | 1994-11-14 | 1994-11-14 | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
US08/338,379 | 1994-11-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR970706830A true KR970706830A (ko) | 1997-12-01 |
KR100411380B1 KR100411380B1 (ko) | 2004-04-30 |
Family
ID=23324592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019970703171A KR100411380B1 (ko) | 1994-11-14 | 1995-11-14 | 시스플라틴과2,2'-디티오-비스(에탄설포네이트)(디메스나)를포함하는조성물 |
Country Status (13)
Country | Link |
---|---|
US (5) | US5789000A (ko) |
EP (1) | EP0792154B1 (ko) |
JP (3) | JP4171526B2 (ko) |
KR (1) | KR100411380B1 (ko) |
CN (2) | CN101987111A (ko) |
AT (1) | ATE237337T1 (ko) |
AU (1) | AU706181B2 (ko) |
CA (1) | CA2202170C (ko) |
DE (1) | DE69530412T2 (ko) |
DK (1) | DK0792154T3 (ko) |
ES (1) | ES2191717T3 (ko) |
PT (1) | PT792154E (ko) |
WO (1) | WO1996014852A1 (ko) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
US6025488A (en) * | 1994-11-14 | 2000-02-15 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
US6037336A (en) * | 1996-09-23 | 2000-03-14 | Bionumerik Pharmaceuticals, Inc. | Reducing toxic effects of carboplatin using dithioethers |
WO1998011898A1 (en) * | 1996-09-23 | 1998-03-26 | Bionumerik Pharmaceuticals, Inc. | Reducing toxic effects of carboplatin using dithioethers |
RU2144374C1 (ru) * | 1998-11-23 | 2000-01-20 | Закрытое акционерное общество "ВАМ" | Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток |
US6312734B1 (en) * | 1998-11-23 | 2001-11-06 | Novelos Therapeutics, Inc. | Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells |
US20070142267A1 (en) * | 1998-11-23 | 2007-06-21 | Novelos Therapeutics, Inc. | Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells |
US6197831B1 (en) * | 1999-02-09 | 2001-03-06 | Bionumerik Pharmaceuticals, Inc. | Method of treating septic shock |
US6034126A (en) * | 1999-05-24 | 2000-03-07 | Bionumerik Pharmaceuticals, Inc. | Method for treating glycol poisoning |
CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
US6156350A (en) * | 1999-12-02 | 2000-12-05 | Corazon Technologies, Inc. | Methods and kits for use in preventing restenosis |
CA2406081C (en) | 2000-04-26 | 2009-12-22 | Oregon Health Sciences University | Administration of a thiol-based chemoprotectant compound |
GB0011903D0 (en) * | 2000-05-18 | 2000-07-05 | Astrazeneca Ab | Combination chemotherapy |
KR20030065502A (ko) * | 2000-11-02 | 2003-08-06 | 슬로안-케테링인스티튜트퍼캔서리서치 | 에이치에스피90 저해제를 이용한 세포독성 제제의 효능을향상시키는 방법 |
US6540733B2 (en) * | 2000-12-29 | 2003-04-01 | Corazon Technologies, Inc. | Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion |
CA2434270A1 (en) * | 2001-01-19 | 2002-07-25 | Bionumerik Pharmaceuticals, Inc. | Use of mesna compounds to prevent adverse reactions to anti-neoplastic compositions |
JP2005508838A (ja) * | 2001-03-23 | 2005-04-07 | アフトン コーポレーション | 膵癌の組合せ治療 |
US20090191232A1 (en) * | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
AU2002326356A1 (en) * | 2001-07-09 | 2003-01-29 | Aphton Corporation | Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
US6352979B1 (en) * | 2001-08-20 | 2002-03-05 | Lucinda Lizcano | Method of treating snakebite and complications resulting therefrom |
IL160960A0 (en) * | 2001-09-24 | 2004-08-31 | Tosk Inc | Reduced toxicity cisplatin formulations and methods for using the same |
US7176192B2 (en) * | 2001-10-26 | 2007-02-13 | Bionumerik Pharmaceuticals, Inc. | Method for treating patients for radiation exposure |
US6596320B1 (en) * | 2002-01-11 | 2003-07-22 | Bionumerik Pharmaceuticals, Inc. | Method for treating cancer having greater efficacy and reduced adverse effects |
JP2006506945A (ja) * | 2002-03-28 | 2006-03-02 | メディカル・カレッジ・オブ・オハイオ | 遺伝子発現プロフィールを使用する非小細胞肺癌の診断および処置のための方法および組成物 |
US8710095B2 (en) * | 2002-04-30 | 2014-04-29 | Bionumerik Pharmaceuticals, Inc. | Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity |
US20040014730A1 (en) * | 2002-07-10 | 2004-01-22 | Frederick Hausheer | Formulations and methods of reducing toxicity of anti-infective agents |
WO2004058274A1 (en) * | 2002-12-21 | 2004-07-15 | Bionumerik Pharmaceuticals, Inc. | Method of treating patients exposed to toxic chemical agents |
EP2260846B1 (en) * | 2003-03-27 | 2018-11-28 | Lankenau Institute for Medical Research | Novel methods for the treatment of cancer |
WO2005058005A2 (en) * | 2003-12-17 | 2005-06-30 | Bionumerik Pharmaceuticals, Inc. | Process for synthesizing disulfides |
WO2005095459A2 (en) * | 2004-03-29 | 2005-10-13 | Receptor Biologix, Inc. | Monoclonal antibodies to gastrin hormone |
US20090111735A1 (en) * | 2004-05-12 | 2009-04-30 | Bionumerik Pharmaceuticals, Inc. | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
US20050256055A1 (en) * | 2004-05-12 | 2005-11-17 | Hausheer Frederick H | Compounds and methods for reducing undesired toxicity of chemotherapeutic agents |
US7282602B2 (en) * | 2004-09-21 | 2007-10-16 | Bionumerik Pharmaceuticals, Inc. | Medicinal disulfide salts |
US7235589B2 (en) | 2004-09-21 | 2007-06-26 | Bio Numerik Pharmaceuticals, Inc. | Method of treating patients undergoing kidney dialysis |
US20060063742A1 (en) * | 2004-09-21 | 2006-03-23 | Hausheer Frederick H | Method of treatment for or protection against lymphedema |
EP2567974A3 (en) | 2004-09-22 | 2013-05-22 | Cancer Advances, Inc., | Monoclonal antibodies to progastrin |
CN100443081C (zh) * | 2005-04-05 | 2008-12-17 | 吴一心 | 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物 |
WO2007065167A1 (en) * | 2005-12-02 | 2007-06-07 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
DK1991237T3 (en) * | 2005-12-13 | 2015-04-27 | Bionumerik Pharmaceuticals Inc | Chemoprotective methods and compositions |
CA2647297A1 (en) * | 2006-03-16 | 2007-09-27 | Bionumerik Pharmaceuticals, Inc. | Anti-cancer activity augmentation compounds and formulations and methods of use thereof |
WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
WO2008034071A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Method of identifying patients suitable for high-dose cyclophosphamide treatment |
WO2008034074A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
CA2677639A1 (en) * | 2007-02-09 | 2008-08-14 | Poniard Pharmaceuticals, Inc. | Encapsulated picoplatin |
TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
CN101809024A (zh) * | 2007-07-16 | 2010-08-18 | 铂雅制药公司 | 吡铂的口服制剂 |
WO2009039190A1 (en) * | 2007-09-17 | 2009-03-26 | Gene Express, Inc. | Cancer risk biomarker |
US9026372B2 (en) * | 2007-11-21 | 2015-05-05 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen |
WO2009067699A2 (en) * | 2007-11-21 | 2009-05-28 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for an oxazaphosphorine drug regimen |
US20110052581A1 (en) * | 2008-02-08 | 2011-03-03 | Poniard Pharmaceuticals Inc. | Use of picoplatin and cetuximab to treat colorectal cancer |
DK2249825T3 (en) * | 2008-03-14 | 2016-01-11 | Bionumerik Pharmaceuticals Inc | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions |
JP5667885B2 (ja) * | 2008-03-14 | 2015-02-12 | バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド | 化学的保護方法及び組成物 |
CA2718233A1 (en) | 2008-03-14 | 2009-09-17 | Bionumerik Pharmaceuticals, Inc. | Compositions and methods of use of compounds to increase cancer patient survival time |
US9320760B2 (en) * | 2008-03-14 | 2016-04-26 | Bionumerik Pharmaceuticals, Inc. | Compositions and methods of use of compounds to increase cancer patient survival time |
US20110064828A1 (en) * | 2009-09-11 | 2011-03-17 | Novelos Therapeutics, Incorporated | Treatment of metastatic tumors and other conditions |
TWI438009B (zh) * | 2010-02-19 | 2014-05-21 | Teikoku Pharma Usa Inc | 紫杉烷前-乳劑調配物及其製造與使用之方法 |
WO2011139899A2 (en) | 2010-05-03 | 2011-11-10 | Teikoku Pharma Usa, Inc. | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
BR112014017833A2 (pt) | 2012-01-20 | 2021-03-23 | Dennis Brown | Uso de hexitóis substituídos incluindo dianidrogalactitol e análogos para tratar doença neoplástica e células-tronco de câncer incluindo glioblastoma multiforme e meduloblastoma |
MX2015000810A (es) * | 2012-07-19 | 2015-06-05 | Relypsa Inc | Composiciones que comprenden polímeros reticulados con enlace a cationes. |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
CA3066756A1 (en) | 2017-06-15 | 2018-12-20 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2806866C3 (de) * | 1978-02-17 | 1981-02-12 | Asta-Werke Ag Chemische Fabrik, 4800 Bielefeld | Verwendung von Salzen von Dithiodialkansulfonsäuren |
US4310515A (en) * | 1978-05-30 | 1982-01-12 | Bristol-Myers Company | Pharmaceutical compositions of cisplatin |
EP0334083B1 (de) * | 1988-03-19 | 1991-07-24 | ASTA Pharma Aktiengesellschaft | Ifosfamid-Mesna-Lyophilisat und Verfahren zu dessen Herstellung |
US5227373A (en) * | 1991-10-23 | 1993-07-13 | Bristol-Myers Squibb Co. | Lyophilized ifosfamide compositions |
JP3954115B2 (ja) * | 1992-07-28 | 2007-08-08 | アストラゼネカ・アクチエボラーグ | 注射剤および注射剤キット |
US5789000A (en) * | 1994-11-14 | 1998-08-04 | Bionumerik Pharmaceuticals, Inc. | Sterile aqueous parenteral formulations of cis-diammine dichloro platinum |
-
1994
- 1994-11-14 US US08/338,379 patent/US5789000A/en not_active Expired - Lifetime
-
1995
- 1995-11-03 US US08/553,005 patent/US5902610A/en not_active Expired - Lifetime
- 1995-11-14 JP JP51574596A patent/JP4171526B2/ja not_active Expired - Fee Related
- 1995-11-14 DE DE69530412T patent/DE69530412T2/de not_active Expired - Lifetime
- 1995-11-14 WO PCT/EP1995/004490 patent/WO1996014852A1/en not_active Application Discontinuation
- 1995-11-14 PT PT95939282T patent/PT792154E/pt unknown
- 1995-11-14 AT AT95939282T patent/ATE237337T1/de active
- 1995-11-14 CA CA002202170A patent/CA2202170C/en not_active Expired - Lifetime
- 1995-11-14 CN CN2010102328968A patent/CN101987111A/zh active Pending
- 1995-11-14 EP EP95939282A patent/EP0792154B1/en not_active Expired - Lifetime
- 1995-11-14 KR KR1019970703171A patent/KR100411380B1/ko active IP Right Grant
- 1995-11-14 CN CN951962310A patent/CN1165483B/zh not_active Expired - Lifetime
- 1995-11-14 DK DK95939282T patent/DK0792154T3/da active
- 1995-11-14 AU AU41168/96A patent/AU706181B2/en not_active Expired
- 1995-11-14 ES ES95939282T patent/ES2191717T3/es not_active Expired - Lifetime
-
1997
- 1997-04-18 US US08/844,544 patent/US5866617A/en not_active Expired - Lifetime
- 1997-04-30 US US08/848,361 patent/US5866615A/en not_active Expired - Lifetime
- 1997-06-18 US US08/878,244 patent/US5866169A/en not_active Expired - Lifetime
-
2008
- 2008-02-28 JP JP2008047977A patent/JP2008133304A/ja active Pending
-
2012
- 2012-08-02 JP JP2012172119A patent/JP2012211198A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JPH10509143A (ja) | 1998-09-08 |
US5902610A (en) | 1999-05-11 |
US5866615A (en) | 1999-02-02 |
US5789000A (en) | 1998-08-04 |
AU706181B2 (en) | 1999-06-10 |
CA2202170A1 (en) | 1996-05-23 |
US5866617A (en) | 1999-02-02 |
JP2008133304A (ja) | 2008-06-12 |
CA2202170C (en) | 2007-04-10 |
ATE237337T1 (de) | 2003-05-15 |
PT792154E (pt) | 2003-09-30 |
MX9703460A (es) | 1997-07-31 |
JP2012211198A (ja) | 2012-11-01 |
DE69530412T2 (de) | 2003-10-30 |
KR100411380B1 (ko) | 2004-04-30 |
JP4171526B2 (ja) | 2008-10-22 |
DE69530412D1 (de) | 2003-05-22 |
WO1996014852A1 (en) | 1996-05-23 |
ES2191717T3 (es) | 2003-09-16 |
EP0792154A1 (en) | 1997-09-03 |
CN1165483A (zh) | 1997-11-19 |
AU4116896A (en) | 1996-06-06 |
US5866169A (en) | 1999-02-02 |
CN1165483B (zh) | 2012-09-05 |
EP0792154B1 (en) | 2003-04-16 |
CN101987111A (zh) | 2011-03-23 |
DK0792154T3 (da) | 2003-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR970706830A (ko) | 2, 2'-디티오-비스(에탄설포네이트)(디메스나)와 조합된 시스플라틴의 조성물(composition of cisplatin in combination with 2, 2'-dithio-bis (ethanesulfonate) (dimesna) | |
BR0214757A (pt) | Formulações farmacêuticas de derivados de platina | |
CO4700482A1 (es) | Formulaciones de un analogo monomero de insulina | |
BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
DE3772521D1 (de) | Insulinzubereitung fuer nicht-parenterale verabreichung. | |
BR9815159A (pt) | Preparação de conjugados de polietileno glicol-grf especìfica ao sìtio | |
BR9508554A (pt) | Preparação farmaceuticamente estável de oxaliplatina | |
BR0009770A (pt) | Derivados de bisindóis indigóides capazes de penetrarem na membrana de células, formulação farmacêutica e utilização da mesma | |
BR0109779A (pt) | Soluções moleculares hidrofìlicas dispersas de carvedilol | |
KR900701282A (ko) | 심장 또는 뇌의 허혈성 질환의 치료, 예방제 | |
BR0013065A (pt) | Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos | |
KR880007514A (ko) | 키놀린 화합물 | |
TR200101633T2 (tr) | Farmasötik bileşim | |
BR0111506A (pt) | Complexos de droga macromoleculares e composições contendo os mesmos | |
TR200101163T2 (tr) | Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları | |
IE81029B1 (en) | Medicine based on neutralized sulphur derivatives | |
BR9712197A (pt) | Formulação farmacêutica líquida aquosa e processos de preparação da mesma, e, de inibição de reabsorção de osso. | |
KR920004387A (ko) | 진통제 및 피부질환 치료용 국소용 소염제로서의 4-치환된 디하이드로피리도[4,3-d]피리미딘 | |
FR2427097A1 (fr) | Medicament sous la forme d'une solution aqueuse sterile stable de cisplatine | |
GEP20043254B (en) | Use of Camptothecin Derivatives with Reduced Gastrointestinal Toxicity | |
KR970706844A (ko) | 트롬빈 억제제를 함유하는 저장 안정성 수용액상 주입액(A Storage Stable Water Solution for Infusion Containing A Thrombin Inhibitor) | |
EP1417970B1 (en) | Anti-allergic, anti-bacteric and anti-redden compound for eyes | |
BR0014233A (pt) | Conjugados de 4-benzilaminoquinolina com ácido galênico e seus heteroanálogos, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação | |
HUP0105359A2 (hu) | Benzamidszármazékok és az azokat tartalmazó gyógyszerkészítmények | |
BR0314651A (pt) | Composição farmacêutica, e, método para tratar infecção pelo hvi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121123 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20131122 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20141121 Year of fee payment: 12 |